Enzon sells speciality pharma unit to sigma-tau for $300 million
This article was originally published in Scrip
Shares in Enzon Pharmaceuticals rose by 9.5% to close at $9.83 on November 9th after it announced the sale of its marketed products business. It has agreed to sell its four speciality pharmaceutical products to Italy's sigma-tau Group for $300 million plus up to $27 million in milestones and certain royalties. The products generated revenues of $29 million in the third quarter, down by 1% on the previous year.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.